Radiopharmaceutical developer Piramal Imaging has been renamed as Life Molecular Imaging (LMI) following its recent acquisition by Alliance Medical Group.
Now part of the Alliance Medical Molecular Imaging division, LMI will continue to offer imaging services, proprietary products, and investigational agents currently in clinical development, according to the firm. LMI's Neuraceq (florbetaben F-18) radiopharmaceutical for beta-amyloid plaque imaging can be used clinically and -- along with other investigational tracers such as PI-2620 for tau imaging -- as part of clinical trials for Alzheimer's disease drug development, the company said.
